HRTG
Heritage Insurance Holdings, Inc.
$21.62
+0.42%
$653.4M
No data for this timeframe.
Vol
Market Cap$653.4M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders8 funds
Inst. Value$85.9M
Inst. Activity2 buys / 2 sells
Insider Activity1B / 9S
Insider Net $-$2.6M
SEC Reports3
Recent Activity
Jun 3, 2026
Event
Amlodipine and Benazepril Hydrochloride
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue amlodipine and benazepril hydrochlor
May 19, 2026
Insider
WHITING PAUL L bought 15,000 shares
Director @ $23.50 ($352.5K)
May 8, 2026
short_volume
Short Volume: HRTG — 60.2% short (0.4M / 0.7M)
Short: 422,886 | Exempt: 19,318 | TRF Vol: 702,241 | Short Ratio: 60.2% | Off-exchange volume (dark
May 7, 2026
SEC
Heritage Insurance reported Q1 2026 EPS of $1.19, missing consensus of $1.53 by 22%, on revenue of $212.7M (1.3% below e
8-K — Impact 6/10
May 1, 2026
Insider
Binnun Sharon sold 9,200 shares
Chief Accounting Officer @ $28.99 ($266.8K)
Apr 20, 2026
SEC
Ernesto Garateix, a director and officer of Heritage Insurance Holdings, filed a Form 144 notifying intent to sell up to
144 — Impact 3/10
Apr 20, 2026
Insider
Garateix Ernie J sold 8,034 shares
Chief Executive Officer @ $27.52 ($221.1K)
Mar 23, 2026
SEC
Three insiders at Heritage Insurance Holdings sold shares in the past week, including CEO Ernie Garateix and Chief Accou
CLUSTER — Impact 7/10
Price Targets
$31.50
+45.7% upside
Strong Buy
Current $21.62
Low $27.00
Median $31.50
High $36.00
2 analysts
$27.00
$36.00
Analyst Ratings
2Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Mar 10, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.18 | $0.99 — $1.35 | -24% YoY | 3 |
| Next Q | $0.57 ▼ -3.4% | $0.51 — $0.62 | -64% YoY | 3 |
| Current FY | $4.23 ▼ -7.3% | $4.05 — $4.50 | -32% YoY | 3 |
| Next FY | $4.58 ▼ -6.8% | $4.10 — $5.20 | 8% YoY | 3 |
Latest Reports
BEARISH
8-K
6/10
Heritage Insurance reported Q1 2026 EPS of $1.19, missing consensus of $1.53 by 22%, on revenue of $212.7M (1.3% below e
May 7, 2026
NEUTRAL
144
3/10
Ernesto Garateix, a director and officer of Heritage Insurance Holdings, filed a Form 144 notifying intent to sell up to
Apr 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $55.0M | — |
| MORGAN STANLEY | $8.0M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $7.5M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $5.3M | TRIM |
| FMR LLC | $3.2M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | WHITING PAUL | BUY | $352.5K |
| May 1, 2026 | Binnun Sharon | SELL | $266.8K |
| Apr 20, 2026 | Garateix Ernie | SELL | $221.1K |
| Apr 2, 2026 | Moura Timothy | SELL | $212.2K |
| Apr 1, 2026 | Binnun Sharon | SELL | $223.5K |
8 institutional holders with $85.9M total value (2,935,087 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,881,027 | $55.0M | 64.1% | — |
| 2 | MORGAN STANLEY | 272,454 | $8.0M | 9.3% | ADD +37.5% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 255,174 | $7.5M | 8.7% | ADD +25.2% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 181,681 | $5.3M | 6.2% | TRIM -33.3% |
| 5 | FMR LLC | 110,418 | $3.2M | 3.8% | TRIM -25.5% |
| 6 | BANK OF AMERICA CORP /DE/ | 101,141 | $3.0M | 3.4% | TRIM -30.9% |
| 7 | TWO SIGMA INVESTMENTS, LP | 83,329 | $2.4M | 2.8% | TRIM -43.5% |
| 8 | WELLS FARGO & COMPANY/MN | 49,863 | $1.5M | 1.7% | ADD +45.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 203,839 | 255,174 | +25.2% | $7.5M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 272,330 | 181,681 | -33.3% | $5.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 146,366 | 101,141 | -30.9% | $3.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 34,300 | 49,863 | +45.4% | $1.5M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 372,999 | 272,330 | -27.0% | $6.9M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 66,666 | 203,839 | +205.8% | $5.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 83,988 | 146,366 | +74.3% | $3.7M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 22,567 | 34,300 | +52.0% | $863.7K | 2025-Q3 |
| MORGAN STANLEY | ADD | 251,730 | 346,055 | +37.5% | $8.6M | 2025-Q2 |
| UBS Group AG | DOUBLED | 48,860 | 242,708 | +396.7% | $6.1M | 2025-Q2 |
| FMR LLC | TRIM | 117,390 | 87,504 | -25.5% | $2.2M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 47,787 | 83,988 | +75.8% | $2.1M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 13,722 | 22,567 | +64.5% | $562.8K | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 244,534 | 308,209 | +26.0% | $4.4M | 2025-Q1 |
| MORGAN STANLEY | ADD | 173,273 | 251,730 | +45.3% | $3.6M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 208,045 | 117,508 | -43.5% | $1.7M | 2025-Q1 |
| UBS Group AG | ADD | 28,856 | 48,860 | +69.3% | $704.6K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 567,199 | 345,399 | -39.1% | $4.2M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 340,011 | 244,534 | -28.1% | $3.0M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 231,992 | 173,273 | -25.3% | $2.1M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 382,054 | 231,992 | -39.3% | $2.8M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 64,066 | — | $784.2K | 2024-Q3 |
6 unique insiders with 10 transactions. Net insider value: -$2.6M ($352.5K bought, $2.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | WHITING PAUL L | Director | BUY | 15,000 | $23.50 | $352.5K |
| May 1, 2026 | Binnun Sharon | Chief Accounting Officer | SELL | 9,200 | $28.99 | $266.8K |
| Apr 20, 2026 | Garateix Ernie J | Chief Executive Officer | SELL | 8,034 | $27.52 | $221.1K |
| Apr 2, 2026 | Moura Timothy | See Remarks | SELL | 8,444 | $25.13 | $212.2K |
| Apr 1, 2026 | Binnun Sharon | Chief Accounting Officer | SELL | 8,700 | $25.69 | $223.5K |
| Apr 1, 2026 | Moura Timothy | See Remarks | SELL | 24,619 | $25.78 | $634.6K |
| Mar 20, 2026 | Garateix Ernie J | Chief Executive Officer | SELL | 8,334 | $25.39 | $211.6K |
| Mar 19, 2026 | Moura Timothy | See Remarks | SELL | 28,223 | $26.60 | $750.8K |
| Mar 17, 2026 | Binnun Sharon | Chief Accounting Officer | SELL | 7,893 | $28.35 | $223.8K |
| Mar 12, 2026 | Moura Timothy | See Remarks | F | 47,549 | $28.14 | $1.3M |
| Mar 12, 2026 | Binnun Sharon | Chief Accounting Officer | F | 36,274 | $28.14 | $1.0M |
| Mar 12, 2026 | Garateix Ernie J | Chief Executive Officer | F | 149,632 | $28.14 | $4.2M |
| Mar 12, 2026 | JOHNS TIMOTHY E | See Remarks | F | 10,588 | $28.14 | $297.9K |
| Mar 12, 2026 | Lusk Kirk | Chief Financial Officer | F | 72,549 | $28.14 | $2.0M |
| Mar 5, 2026 | JOHNS TIMOTHY E | See Remarks | A | 764 | $0.00 | $0.00 |
| Mar 5, 2026 | Lusk Kirk | Chief Financial Officer | A | 15,271 | $0.00 | $0.00 |
| Mar 5, 2026 | Garateix Ernie J | Chief Executive Officer | A | 25,960 | $0.00 | $0.00 |
| Mar 5, 2026 | Binnun Sharon | Chief Accounting Officer | A | 3,037 | $0.00 | $0.00 |
| Mar 5, 2026 | Moura Timothy | See Remarks | A | 4,337 | $0.00 | $0.00 |
| Feb 20, 2026 | Garateix Ernie J | Chief Executive Officer | SELL | 8,134 | $24.10 | $196.0K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
BEARISH
8-K
6/10
Heritage Insurance reported Q1 2026 EPS of $1.19, missing consensus of $1.53 by 22%, on revenue of $
May 7, 2026
NEUTRAL
144
3/10
Ernesto Garateix, a director and officer of Heritage Insurance Holdings, filed a Form 144 notifying
Apr 20, 2026
BEARISH
CLUSTER
7/10
Three insiders at Heritage Insurance Holdings sold shares in the past week, including CEO Ernie Gara
Mar 23, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (78% buy). Based on 9 analysts: 2 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$31.50 mean target
+45.7% upside
Strong Buy (3.00)
$27.00 Low
$36.00 High
| Metric | Value |
|---|---|
| Current Price | $21.62 |
| Target Low | $27.00 |
| Target Mean | $31.50 |
| Target Median | $31.50 |
| Target High | $36.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.18 | $0.99 | $1.35 | -24.1% | +0.3% | 1↑ 2↓ | $0.2B | 2.3% | 3 |
| Next Q 2026-09-30 |
$0.57 | $0.51 | $0.62 | -63.7% | -3.4% | 1↑ 2↓ | $0.2B | 2.0% | 3 |
| Current FY 2026-12-31 |
$4.23 | $4.05 | $4.50 | -32.3% | -7.3% | 0↑ 3↓ | $0.9B | 1.6% | 3 |
| Next FY 2027-12-31 |
$4.58 | $4.10 | $5.20 | 8.3% | -6.8% | 0↑ 3↓ | $0.9B | 4.4% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.177 | |
| 7d ago | $1.170 | +0.007 |
| 30d ago | $1.173 | +0.003 |
| 60d ago | $1.173 | +0.003 |
| 90d ago | $1.035 | +0.142 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| May 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jan 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
FDA
Amlodipine and Benazepril Hydrochloride
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue amlodipine and benazepril hydrochloride capsules as soon as possible (5.1) . Drugs tha
May 12, 2026
FDA
Tranexamic Acid
WARNING: RISK OF MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION Tranexamic acid injection is for intravenous use only. Serious, including
May 11, 2026
FDA
Midazolam hydrochloride
WARNINGS Personnel and Equipment for Monitoring and Resuscitation Adults and Pediatrics: Intravenous midazolam hydrochloride has been associated with
May 8, 2026
short_volume
Short Volume: HRTG — 60.2% short (0.4M / 0.7M)
Short: 422,886 | Exempt: 19,318 | TRF Vol: 702,241 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
HRTG Q1 2026 Earnings Scheduled — 2026-05-07
Mar 9, 2026
earnings_calendar
HRTG Q4 2025 Earnings After Market Close — 2026-03-09
Mar 3, 2026
FDA
glyburide-metformin hydrochloride
WARNING: LACTIC ACIDOSIS WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hyp
Feb 26, 2026
earnings_calendar
HRTG Q4 2025 Earnings After Market Close — 2026-02-26